Immunotherapy after chemoradiotherapy did not improve PFS or OS in limited stage SCLC

At ASCO 2025, Professor and Consultant in Oncology Bjørn Henning Grønberg (NTNU and St. Olavs Hospital, Trondheim) presented findings from an international, multicenter study involving 216 patients across 37 European hospitals with limited-stage small cell lung cancer.
The study evaluated whether consolidation treatment with atezolizumab following chemoradiotherapy could improve survival in this group of patients.Although the trial did not meet its primary endpoint of progression-free or overall survival benefit, atezolizumab was well tolerated.
The results contribute important insights to the ongoing discussion about the role of immunotherapy in the setting for limited-stage small cell lung cancer and highlight the need for further investigation for this patient population.